Processing your request

please wait...

Case Page


Case Status:    ONGOING    
On or around 09/23/2019 (Date of last review)

Filing Date: December 01, 2017

INCR provides Phase I to Phase IV clinical development services to pharmaceutical, biotechnology, and medical device companies.

According to the law firm press release, on August 1, 2017, the Company announced that it completed a merger (the “Merger”) with inVentiv Health, Inc. (“inVentiv”). And, the Company represented to investors that the Merger was the beginning of an industry changing company, with high expectations for revenue growth and profitability. However, on November 9, 2017, the first quarter after the Merger, INCR reported a net loss of $88.9 million, as well as impairment charges to the Company’s intangible assets. Analysts noted that the Company’s fourth quarter guidance was worrisome given the challenges that inVentiv’s commercial business faced.

On this news, the Company’s stock price fell $16.35 per share, or 28.4%, to close at $41.15 per share on November 9, 2017, on unusually heavy trading volume. The Company’s share price continued to fall over the next three trading sessions, closing on November 14, 2017 at $34.35 per share, a total decline of $23.15 per share, or 40.3%.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Merger was not providing the benefit that Defendants stated it would; (2) that inVentiv was underperforming; (3) that, as a result, the Company’s 2017 financial performance would be negatively impacted; and (4) that, as a result of the foregoing, Defendants’ statements about INCR’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

This case was voluntarily dismissed on March 30, 2018. A related case continues under Docket 18-CV-00029 in the Eastern District of North Carolina.

On May 29, 2018, the Court issued an Order appointing Lead Plaintiffs and Counsel. Lead Plaintiffs filed an amended Complaint on July 30, 2018. On September 23, 2019, the Court issued an Order staying the case pending resolution of a related case proceeding in the District of New Jersey.


Sector: Services
Industry: Business Services
Headquarters: United States


Ticker Symbol: INCR
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 17-CV-09457
JUDGE: Hon. Paul G. Gardephe
DATE FILED: 12/01/2017
CLASS PERIOD END: 11/09/2017
  1. Glancy Prongay & Murray LLP (New York)
  2. Holzer & Holzer, LLC
No Document Title Filing Date
COURT: E.D. North Carolina
DOCKET #: 18-CV-00029
JUDGE: Hon. Paul G. Gardephe
DATE FILED: 07/30/2018
CLASS PERIOD END: 11/08/2017
  1. McDaniel & Anderson, LLP
    4942 Windy Hill Drive; P.O. Box 58186, McDaniel & Anderson, LLP, NC 27658
    919.872.3000 ·
  2. Robbins Geller Rudman & Dowd LLP (Boca Raton)
    120 East Palmetto Park Road, Suite 500, Robbins Geller Rudman & Dowd LLP (Boca Raton), FL 33432
    561.750.3000 561.750.3364 ·
No Document Title Filing Date
—Related District Court Filings Data is not available